Álvaro Rodríguez Lescure-rekin lankidetzan egindako argitalpenak (8)

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2016

  1. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

    Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89

2011

  1. Hormone-responsive breast cancer

    Advances in Therapy, Vol. 28, Núm. 12, pp. 1045-1058

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

  3. Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

    Annals of Oncology

2007

  1. The use of taxanes in the neoadjuvant treatment of breast cancer: A review of randomized phase II/III trials

    Clinical Breast Cancer, Vol. 7, Núm. 10, pp. 764-774